CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DEGFRW731LPredictiveSupportsSensitivity/ResponseCancerErlotinibFoster et al., 2010
DEGFRE734QPredictiveSupportsSensitivity/ResponseCancerErlotinibFoster et al., 2010
DEGFRT785APredictiveSupportsSensitivity/ResponseCancerErlotinibFoster et al., 2010
DEGFRC797YPredictiveSupportsSensitivity/ResponseCancerErlotinibFoster et al., 2010
DEGFRY801HPredictiveSupportsSensitivity/ResponseCancerErlotinibFoster et al., 2010
CEGFRL747_S752delinsQPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaErlotinibPao et al., 2004
CEGFRL861RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
CBCR::ABL1Fusion AND ABL1 D363GPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 V379IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 E98GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceAcute Lymphoblastic LeukemiaDasatinibTalpaz et al., 2006
CPOLD1C284YPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaPembrolizumabRizvi et al., 2015
DBRAFV600E AND PIK3R2 N561DPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
DABL1G340LPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDasatinib,Imatinib MesylateTestoni et al., 2016
CEGFRP772_H773insYNPPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinibYasuda et al., 2013
CEGFRP772_V774insPHVPredictiveDoes Not SupportSensitivity/ResponseLung AdenocarcinomaErlotinibYasuda et al., 2013
CJAK2Splice Site (c.1641+2T>G)PredictiveSupportsResistanceMelanomaPembrolizumabZaretsky et al., 2016
BCDK4AmplificationPredictiveSupportsSensitivity/ResponseLiposarcomaPalbociclibDickson et al., 2016
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAbemaciclibPatnaik et al., 2016
BACVR1Gain-of-FunctionDiagnosticSupportsPositiveMalignant AstrocytomaFontebasso et al., 2014
BACVR1G328VDiagnosticSupportsPositiveDiffuse Midline Glioma, H3 K27M-mutantFontebasso et al., 2014
Bv::RETFusionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCabozantinibDrilon et al., 2016
Bv::RETFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaVandetanibLee et al., 2017
Bv::RETFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaVandetanibYoh et al., 2017
Cv::RETFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAlectinibLin et al., 2016
BCD274ExpressionPrognosticSupportsPoor OutcomeBreast CancerZhang et al., 2017
BCD274ExpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAtezolizumab,Pembrolizumab,Nivolumab,Durvalumab,AvelumabAguiar et al., 2017
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,DacomitinibRamalingam et al., 2016
CFGFR3::TACC3Fusion AND FGFR2::CCDC6 FusionPredictiveSupportsSensitivity/ResponseAdrenal CarcinomaErdafitinibTabernero et al., 2015
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrametinib,Pemetrexed,DocetaxelGandara et al., 2017
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaNivolumab,AtezolizumabKim et al., 2017
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerSelumetinib,CetuximabDeming et al., 2016
BBRCA2Loss-of-functionPredictiveSupportsSensitivity/ResponseOvarian CancerTalazoparibde Bono et al., 2017
BBRCA1Loss-of-functionPredictiveSupportsSensitivity/ResponseOvarian CancerTalazoparibde Bono et al., 2017
BEGFRExpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibFukuoka et al., 2003
DTP53R175HPredictiveSupportsResistanceBreast AdenocarcinomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53M237IPredictiveSupportsResistanceGlioblastomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R158HPredictiveSupportsResistanceVulva Squamous Cell CarcinomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
CVHLE55* (c.163G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseLosonczy et al., 2013
CBRAFL597QPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinibBowyer et al., 2014
CVHLY98H (c.292T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLR167Q (c.500G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLL178P (c.533T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLS65W (c.194C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLN78H (c.232A>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLN78S (c.233A>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLS80I (c.239G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLW117C (c.351G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
CVHLL129Q (c.386insAGA)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseChen et al., 1995
Page 45 of 96
PreviousNext